Literature DB >> 34407349

Lorlatinib in a Child with ALK-Fusion-Positive High-Grade Glioma.

Aditi Bagchi1, Brent A Orr1, Olivia Campagne1, Sandeep Dhanda1, Sreenath Nair1, Quynh Tran1, Anthony M Christensen1, Amar Gajjar1, Larissa V Furtado1, Aksana Vasilyeva1, Frederick Boop2, Clinton Stewart3, Giles W Robinson3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34407349      PMCID: PMC8672682          DOI: 10.1056/NEJMc2101264

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   176.079


× No keyword cloud information.
  4 in total

1.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Authors:  Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

2.  Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

Authors:  Matthew Clarke; Alan Mackay; Britta Ismer; Jessica C Pickles; Ruth G Tatevossian; Scott Newman; Tejus A Bale; Iris Stoler; Elisa Izquierdo; Sara Temelso; Diana M Carvalho; Valeria Molinari; Anna Burford; Louise Howell; Alex Virasami; Amy R Fairchild; Aimee Avery; Jane Chalker; Mark Kristiansen; Kelly Haupfear; James D Dalton; Wilda Orisme; Ji Wen; Michael Hubank; Kathreena M Kurian; Catherine Rowe; Mellissa Maybury; Stephen Crosier; Jeffrey Knipstein; Ulrich Schüller; Uwe Kordes; David E Kram; Matija Snuderl; Leslie Bridges; Andrew J Martin; Lawrence J Doey; Safa Al-Sarraj; Christopher Chandler; Bassel Zebian; Claire Cairns; Rachael Natrajan; Jessica K R Boult; Simon P Robinson; Martin Sill; Ira J Dunkel; Stephen W Gilheeney; Marc K Rosenblum; Debbie Hughes; Paula Z Proszek; Tobey J Macdonald; Matthias Preusser; Christine Haberler; Irene Slavc; Roger Packer; Ho-Keung Ng; Shani Caspi; Mara Popović; Barbara Faganel Kotnik; Matthew D Wood; Lissa Baird; Monika Ashok Davare; David A Solomon; Thale Kristin Olsen; Petter Brandal; Michael Farrell; Jane B Cryan; Michael Capra; Michael Karremann; Jens Schittenhelm; Martin U Schuhmann; Martin Ebinger; Winand N M Dinjens; Kornelius Kerl; Simone Hettmer; Torsten Pietsch; Felipe Andreiuolo; Pablo Hernáiz Driever; Andrey Korshunov; Lotte Hiddingh; Barbara C Worst; Dominik Sturm; Marc Zuckermann; Olaf Witt; Tabitha Bloom; Clare Mitchell; Evelina Miele; Giovanna Stefania Colafati; Francesca Diomedi-Camassei; Simon Bailey; Andrew S Moore; Timothy E G Hassall; Stephen P Lowis; Maria Tsoli; Mark J Cowley; David S Ziegler; Matthias A Karajannis; Kristian Aquilina; Darren R Hargrave; Fernando Carceller; Lynley V Marshall; Andreas von Deimling; Christof M Kramm; Stefan M Pfister; Felix Sahm; Suzanne J Baker; Angela Mastronuzzi; Andrea Carai; Maria Vinci; David Capper; Sergey Popov; David W Ellison; Thomas S Jacques; David T W Jones; Chris Jones
Journal:  Cancer Discov       Date:  2020-04-01       Impact factor: 39.397

3.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Authors:  Ana S Guerreiro Stucklin; Scott Ryall; Kohei Fukuoka; Michal Zapotocky; Alvaro Lassaletta; Christopher Li; Taylor Bridge; Byungjin Kim; Anthony Arnoldo; Paul E Kowalski; Yvonne Zhong; Monique Johnson; Claire Li; Arun K Ramani; Robert Siddaway; Liana Figueiredo Nobre; Pasqualino de Antonellis; Christopher Dunham; Sylvia Cheng; Daniel R Boué; Jonathan L Finlay; Scott L Coven; Inmaculada de Prada; Marta Perez-Somarriba; Claudia C Faria; Michael A Grotzer; Elisabeth Rushing; David Sumerauer; Josef Zamecnik; Lenka Krskova; Miguel Garcia Ariza; Ofelia Cruz; Andres Morales La Madrid; Palma Solano; Keita Terashima; Yoshiko Nakano; Koichi Ichimura; Motoo Nagane; Hiroaki Sakamoto; Maria Joao Gil-da-Costa; Roberto Silva; Donna L Johnston; Jean Michaud; Bev Wilson; Frank K H van Landeghem; Angelica Oviedo; P Daniel McNeely; Bruce Crooks; Iris Fried; Nataliya Zhukova; Jordan R Hansford; Amulya Nageswararao; Livia Garzia; Mary Shago; Michael Brudno; Meredith S Irwin; Ute Bartels; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Uri Tabori; Cynthia Hawkins
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

Review 4.  High-grade glioma in very young children: a rare and particular patient population.

Authors:  Moatasem El-Ayadi; Marc Ansari; Dominik Sturm; Gerrit H Gielen; Monika Warmuth-Metz; Christof M Kramm; Andre O von Bueren
Journal:  Oncotarget       Date:  2017-06-14
  4 in total
  2 in total

1.  N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.

Authors:  You-Qing Miao; Wei Chen; Jianfeng Zhou; Qiyang Shen; Ying Sun; Tao Li; Sheng-Chan Wang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

2.  NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun.

Authors:  Zigui Chen; Yingying Xie; Hongcheng Luo; Ye Song; Tianshi Que; Rentong Hu; Huatuo Huang; Kunxiang Luo; Chuanyu Li; Chengjian Qin; Chuanhua Zheng; Weiyi Fang; Longyang Liu; Hao Long; Qisheng Luo
Journal:  Aging (Albany NY)       Date:  2021-12-27       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.